Log In or Create Account
CROI
Conference on Bacteriophages
RWHAP Clinical Conference
Podcasts
Slides
Question of the Week
Donate
Contact
Advanced Search
CME Courses
HIV In-Person and Virtual Courses
Current On-Demand Courses
About Courses
CME Webinars
Upcoming Webinars
Current On-Demand Webinars
MATE Act CME
About Webinars
Dialogues
Upcoming IAS–USA Dialogues
On-Demand Dialogues
About Dialogues
Topics In Antiviral Medicine
Current Issues for CME
Previous Issues
TAM
Policies and Practices
Permission Request Form
HIV Drug Resistance
Drug Resistance Mutations Chart
Recent Webinars
Journal Articles
Fellow Resources
Fellow Resources
IAS-USA Guidelines and Recommendations
On-Demand Webcasts
Research Collaborations
Additional Resources
About
Scientific Leadership Board
IAS-USA Leadership Award Recipients
Core Faculty
Mission
Staff
CME
Funding Information
Careers
Website Policies
Governance
Suggestions and Recommendations from San Francisco Locals
FAQs
Menu
Daniel C. Douek, MD, PhD
Daniel C. Douek, MD, PhD
Bethesda, MD
CROI
Conference on Bacteriophages
RWHAP Clinical Conference
Podcasts
Slides
Question of the Week
Donate
Contact
CME Courses
HIV In-Person and Virtual Courses
Current On-Demand Courses
About Courses
CME Webinars
Upcoming Webinars
Current On-Demand Webinars
MATE Act CME
About Webinars
Dialogues
Upcoming IAS–USA Dialogues
On-Demand Dialogues
About Dialogues
Topics In Antiviral Medicine
Current Issues for CME
Previous Issues
TAM
Policies and Practices
Permission Request Form
HIV Drug Resistance
Drug Resistance Mutations Chart
Recent Webinars
Journal Articles
Fellow Resources
Fellow Resources
IAS-USA Guidelines and Recommendations
On-Demand Webcasts
Research Collaborations
Additional Resources
About
Scientific Leadership Board
IAS-USA Leadership Award Recipients
Core Faculty
Mission
Staff
CME
Funding Information
Careers
Website Policies
Governance
Suggestions and Recommendations from San Francisco Locals
FAQs
Practice Question of the Week
July 14, 2025: Postexposure Prophylaxis for SARS-CoV-2
Which of the following antiviral drugs has shown efficacy for postexposure prophylaxis (PEP) of SARS-CoV-2?
A. Nirmatrelvir/ritonavir
B. Ensitrelvir
C. Molnupiravir
D. Remdesivir
View the Issue
View Archived Questions
Leave Feedback
Subscribe
CLOSE
